MedTrace Logo

CHF6467 SAD and MAD in Patients With Diabetic Foot Ulcer

NCT04077671 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2022-02-23

No results posted yet for this study

Summary

To assess the safety and tolerability of single and multiple days' topical dosing with CHF6467 in subjects with diabetic foot ulcer (DFU).

Conditions

  • Diabetic Neuropathic Foot Ulcers

Interventions

BIOLOGICAL

CHF6467 active

CHF6467, is mutated form of the human Nerve Growth Factor (NGF).

Sponsors & Collaborators

  • Comac Medical

    collaborator INDUSTRY

  • Chiesi Farmaceutici S.p.A.

    lead INDUSTRY

Principal Investigators

  • Iliya Lozev, MD · Comac Medical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-17
Primary Completion
2021-01-07
Completion
2021-01-07

Countries

  • Bulgaria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04077671 on ClinicalTrials.gov